PhRMA filed a complaint on Wednesday in the U.S. District Court for the District of Columbia, challenging a Medicare Part B pilot that would anchor U.S. drug reimbursement to international reference prices. The suit targets the so-called "most-favored-nation" program, dubbed GLOBE, which the administration finalized on September 30.

The Pharmaceutical Research and Manufacturers of America asserts the pilot exceeds Medicare's statutory authority. The complaint marks the trade group's most direct legal confrontation yet with the administration's pricing agenda, which has relied primarily on voluntary manufacturer agreements to date.

The GLOBE pilot is not expected to materially affect R&D budgets in the near term, because the administration has exempted all but a handful of companies from mandatory participation. Those exempted firms accepted separate deals to charge Medicaid MFN prices — a structure that shifts the legal battlefield from regulatory rulemaking to contract enforcement.

What does the lawsuit mean for R&D portfolio planning?

R&D managers should read the complaint as a signal rather than an immediate budget shock. The pilot's design insulates the largest revenue-generating products from mandatory price compression. But the legal theory — that HHS lacks statutory authority to benchmark Part B reimbursement to foreign prices — could undermine any future expansion.

If the court agrees with PhRMA, agencies would need fresh congressional authority to extend reference pricing beyond the current narrow scope. If the administration prevails, the precedent would lower the legal barrier to scaling GLOBE, with downstream effects on long-range revenue assumptions for biologic and specialty-drug pipelines.

How narrow is the pilot's reach?

The administration carved out voluntary MFN Medicaid agreements as the price for exemption. Only a small set of manufacturers fall inside GLOBE's mandatory scope, and the program is unlikely to deliver the savings originally projected under earlier reference-pricing models.

That limited reach reduces immediate pricing risk for most R&D portfolios. For products inside the pilot, however, developers should expect modeled Part B revenues to shift downward on any launch forecast updated to reflect GLOBE pricing.

What is the procedural timeline?

The case now moves into federal court in Washington. Outcomes in statutory-authority challenges typically unfold over 12 to 24 months, meaning the practical effect on 2027 and 2028 launch planning remains unsettled. Companies with Medicare Part B-exposed assets should track the docket for motions on preliminary injunction and any agency motion to dismiss.

PhRMA framed the complaint around statutory overreach rather than the policy merits of reference pricing. The legal question for the court is whether Congress, in enacting the Medicare statute, granted HHS the discretion to import foreign price benchmarks into Part B reimbursement formulas.

What should R&D leaders do now?

• Update launch-revenue models for any GLOBE-scoped product to reflect mandatory MFN pricing
• Preserve optionality in pipeline prioritization until the court rules on statutory authority
• Treat the Medicaid MFN agreements as a parallel track that may shape future negotiations on commercial pricing
• Monitor HHS rulemaking for any expansion signals if the administration wins the case

The lawsuit lands roughly seven months before the program would take operational effect, giving research sponsors a window to reassess assumptions without forcing an immediate portfolio reset. Whether the case succeeds or fails, the parallel Medicaid MFN framework already in place means the legal precedent will weigh more heavily on future pricing pilots than on the products already locked into voluntary deals.